Published in Cancer Treat Rev on September 07, 2008
Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov (2012) 2.33
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One (2010) 1.28
Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23
Protein kinase C and toll-like receptor signaling. Enzyme Res (2011) 1.14
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology (2013) 1.04
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J Biol Inorg Chem (2009) 0.96
Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization. J Biol Chem (2010) 0.92
Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol (2010) 0.91
Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene (2012) 0.89
PKC signaling in glioblastoma. Cancer Biol Ther (2013) 0.87
Tight junctions in human pancreatic duct epithelial cells. Tissue Barriers (2013) 0.87
Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy. Ann Neurol (2011) 0.86
Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PLoS One (2014) 0.85
HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread. PLoS One (2014) 0.85
Proteomic characterization of HIV-modulated membrane receptors, kinases and signaling proteins involved in novel angiogenic pathways. J Transl Med (2009) 0.85
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta (2014) 0.84
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs (2010) 0.83
Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer. World J Gastroenterol (2014) 0.82
Splice variant PRKC-ζ(-PrC) is a novel biomarker of human prostate cancer. Br J Cancer (2012) 0.82
Sequential activation of classic PKC and estrogen receptor α is involved in estradiol 17ß-D-glucuronide-induced cholestasis. PLoS One (2012) 0.82
Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells. Prostate (2010) 0.81
Exploring the function of protein kinases in schistosomes: perspectives from the laboratory and from comparative genomics. Front Genet (2014) 0.80
Protein kinase C and extracellular signal-regulated kinase regulate movement, attachment, pairing and egg release in Schistosoma mansoni. PLoS Negl Trop Dis (2014) 0.80
Alpinetin activates the δ receptor instead of the κ and μ receptor pathways to protect against rat myocardial cell apoptosis. Exp Ther Med (2013) 0.80
Inhibition of δ-opioid receptors induces brain glioma cell apoptosis through the mitochondrial and protein kinase C pathways. Oncol Lett (2013) 0.79
Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis. J Surg Res (2010) 0.79
Regulation of the Ste20-like kinase, SLK: involvement of activation segment phosphorylation. J Biol Chem (2011) 0.78
PKC-Theta in Regulatory and Effector T-cell Functions. Front Immunol (2015) 0.77
Investigation of anti-cancer mechanisms by comparative analysis of naked mole rat and rat. BMC Syst Biol (2013) 0.76
Alcohol binding in the C1 (C1A+C1B) domain of protein kinase C epsilon. Biochim Biophys Acta (2015) 0.76
Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. Sci Rep (2015) 0.76
Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C. Br J Cancer (2011) 0.76
Proteomic Analysis of the Excretory and Secretory Proteins of Haemonchus contortus (HcESP) Binding to Goat PBMCs In Vivo Revealed Stage-Specific Binding Profiles. PLoS One (2016) 0.76
Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscle. J Cell Mol Med (2014) 0.75
Molecular characterization of protein kinase C delta (PKCδ)-Smac interactions. BMC Biochem (2016) 0.75
Role of tight junctions in signal transduction: an update. EXCLI J (2014) 0.75
Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division. Acta Naturae (2011) 0.75
Identification and characterisation of lamprey protein kinase C delta-like gene. Sci Rep (2017) 0.75
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res (2006) 2.99
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem (2006) 2.90
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res (2010) 2.75
Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res (2007) 2.71
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells (2009) 2.64
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2007) 2.58
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol (2004) 2.55
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res (2010) 2.50
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther (2006) 2.44
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res (2005) 2.21
Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol (2010) 2.15
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res (2005) 2.13
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys (2004) 2.12
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) (2011) 2.10
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Multi-targeted therapy of cancer by genistein. Cancer Lett (2008) 2.02
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol (2007) 2.00
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 1.93
Retracted Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer (2006) 1.89
Emerging role of Notch in stem cells and cancer. Cancer Lett (2008) 1.88
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One (2011) 1.82
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets (2010) 1.75
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 1.74
Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol (2009) 1.68
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res (2002) 1.67
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev (2009) 1.63
Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat (2010) 1.61
Retracted Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem (2009) 1.60
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem (2007) 1.60
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1.59
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res (2008) 1.59
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res (2008) 1.59
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res (2005) 1.57
Retracted FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat (2009) 1.57
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res (2007) 1.56
Antioxidant effect of zinc in humans. Free Radic Biol Med (2004) 1.56
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer (2006) 1.50
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol (2010) 1.49
Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol (2003) 1.49
Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res (2010) 1.48
Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res (2009) 1.48
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 1.46
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther (2008) 1.46
Retracted Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer (2006) 1.44
Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther (2005) 1.44
Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology (2012) 1.44
Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev (2010) 1.44
From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther (2008) 1.43
New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res (2009) 1.42
Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42
Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett (2009) 1.42
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res (2007) 1.37
Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res (2002) 1.36
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res (2009) 1.35
MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis (2011) 1.33